Amendment allows for the development of IVD test kits compatible with Illumina technology TUCSON, Ariz.n  On April 30, 2019, HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has amended its IVD Test Developmentand Component Supply Agreement with Illumina, Inc. (Illumina), previously amended in June 2017, to enable the expansion … Continue reading HTG Molecular Expands Agreement with Illumina to Include Autoimmune, Cardiovascular, and Fibrosis Disorders and Diseases